GURU.Markets stock price, segment price, and overall market index valuation
The company's share price MBRX
Moleculin is an oncology company with a broad pipeline of drug candidates. Its stock price reflects the risks and opportunities associated with each of its clinical projects. The chart is a history of successes and failures in drug development.
Share prices of companies in the market segment - Oncology platforms
Moleculin Biotech is an oncology company with a broad pipeline of developments targeting difficult-to-treat cancers. We've classified it as an "Oncology Platform." The chart below shows how investors value biotech companies with diversified treatment approaches.
Broad Market Index - GURU.Markets
Moleculin Biotech is an oncology company developing drugs to treat difficult-to-treat cancers. Its scientific advancements make it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Moleculin shares compare to the broader market.
Change in the price of a company, segment, and market as a whole per day
MBRX - Daily change in the company's share price MBRX
Moleculin Biotech, Inc.'s daily price change reflects the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its oncology drugs, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Oncology platforms
Moleculin Biotech is another oncology biotech stock where shares can rise or fall on clinical trial news. The chart below shows the average daily volatility of this sector. This is an important benchmark for understanding how the company's risks compare to the overall industry environment.
Daily change in the price of a broad market stock, index - GURU.Markets
Moleculin Biotech is a biotech company with a broad oncology pipeline. Its shares react to news across multiple clinical programs. This complex, multi-factorial dynamic contributes uniquely to the overall volatility of the healthcare sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization MBRX
For Moleculin Biotech, Inc., year-over-year performance tells the story of its diversified oncology portfolio. Its 12-month market cap is highly volatile and depends on news from its various clinical programs, from brain cancer to acute myeloid leukemia. Success in any of its candidates could dramatically change its valuation.
Annual dynamics of market capitalization of the market segment - Oncology platforms
Moleculin Biotech, Inc. is a clinical-stage biotechnology company with a diversified portfolio of cancer treatments. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Moleculin Biotech, with its portfolio of oncology drugs, represents a diversified biotech bet. Its performance relative to the market is a combined assessment of the prospects of its several developments. The success of even one drug can lead to explosive growth, far outpacing the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization MBRX
Moleculin is a clinical-stage oncology company with a broad pipeline. Its monthly performance reflects news across its many programs. Progress in any one of them can significantly impact its valuation.
Monthly dynamics of market capitalization of the market segment - Oncology platforms
Moleculin Biotech is a clinical-stage oncology company with a diversified pipeline of drug candidates targeting difficult-to-treat cancers. The chart below illustrates the dynamics of the biotech sector, where investors are evaluating the potential of unique scientific platforms like Moleculin's.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Moleculin Biotech is a biotech company with a broad portfolio of cancer treatments. Diversification can reduce risk, but shares still move primarily on news about clinical trials. Their performance reflects scientific progress, not the state of the economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization MBRX
Moleculin Biotech is an oncology company with several drug candidates in development. Its weekly stock price reflects expectations for its various clinical programs, making it highly volatile.
Weekly dynamics of market capitalization of the market segment - Oncology platforms
Moleculin Biotech is an oncology company with several platforms in development. The chart shows how the company's shares react to news in each area relative to the sector. Is its volatility above average due to its diversified but risky portfolio?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Moleculin Biotech is another biotech company whose stock exists in its own universe, reacting to clinical trial data. The chart clearly demonstrates how its weekly performance is isolated from general market fluctuations, following its own unique scientific trajectory.
Market capitalization of the company, segment and market as a whole
MBRX - Market capitalization of the company MBRX
Moleculin Biotech's market capitalization is a visualization of hope in the fight against intractable cancer. This company's chart reflects investors' faith in its pipeline of experimental drugs targeting brain and pancreatic tumors. It's a highly volatile curve of scientific discovery.
MBRX - Share of the company's market capitalization MBRX within the market segment - Oncology platforms
Moleculin Biotech is a biopharmaceutical company developing a portfolio of drugs for the treatment of difficult-to-treat cancers. Its market capitalization within the oncology platform segment reflects its diversified approach. The company's market capitalization is a composite score for the success rate of its multiple programs, reducing its reliance on a single drug candidate.
Market capitalization of the market segment - Oncology platforms
Moleculin Biotech is an oncology company with a broad development pipeline. How big is this arena? The chart below shows the pulse of the entire oncology platform sector. Its high volatility reflects how investors value companies betting on several different scientific approaches to fighting cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Moleculin Biotech chart shows how the market values an oncology company with a broad pipeline. Its market cap is a bet on one or more of its molecules targeting difficult-to-treat cancers. This diagram illustrates how risk diversification works within a single biotech company.
Book value capitalization of the company, segment and market as a whole
MBRX - Book value capitalization of the company MBRX
For Moleculin Biotech, an oncology company, book value is its tangible asset base, consisting of the rights to a pipeline of drug candidates and significant financial reserves for conducting numerous clinical trials. The chart below shows how this scientific and financial capital has changed.
MBRX - Share of the company's book capitalization MBRX within the market segment - Oncology platforms
Moleculin Biotech, Inc. is an oncology company whose tangible assets are research laboratories developing several platforms to combat difficult-to-treat cancers. The chart shows the share of this diversified R&D infrastructure the company controls.
Market segment balance sheet capitalization - Oncology platforms
Moleculin Biotech is an oncology company. The pharmaceutical industry, as the graph shows, is both knowledge- and capital-intensive. Moleculin focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Moleculin's assets are not a single drug, but a portfolio of developments and patents covering several platforms for developing drugs against difficult-to-treat cancers. The company's book value reflects the capital it invests in clinical trials of its diverse candidates.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - MBRX
Moleculin Biotech is an oncology company with several drug candidates. Its market capitalization is the combined value of its pipeline. The chart shows how investors react to news in each of its clinical pipelines.
Market to book capitalization ratio in a market segment - Oncology platforms
Moleculin Biotech is a biotech company developing drugs to treat difficult-to-treat cancers. Its value is based on the potential of its unique molecules and scientific platforms. The chart shows the high valuation of its development pipeline by investors.
Market to book capitalization ratio for the market as a whole
Moleculin Biotech is developing a platform for creating cancer drugs. Its value lies not in the laboratories, but in the scientific platform itself and its patent portfolio. This chart shows how investors value biotech companies capable of generating multiple potential drugs from a single technology.
Debts of the company, segment and market as a whole
MBRX - Company debts MBRX
Moleculin Biotech is a biotech company with a broad portfolio of oncology drug candidates. Funding multiple clinical programs simultaneously requires significant capital. This chart shows how the company allocates its financial resources and raises funds to support its diverse cancer research.
Market segment debts - Oncology platforms
Moleculin Biotech is a clinical-stage oncology company with a diversified pipeline of drug candidates. Funding multiple clinical programs simultaneously requires significant resources. This chart shows its financial position and ability to support its numerous research projects.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio MBRX
Moleculin Biotech is a biotech company developing cancer treatments. This chart shows its financial structure. Debt during clinical trials is a significant burden for the company, diverting resources from its primary goal—successfully completing research and saving patients' lives.
Market segment debt to market segment book capitalization - Oncology platforms
Moleculin Biotech is a biopharmaceutical company with a broad portfolio of cancer treatment candidates, including difficult-to-treat forms. This diversified approach requires significant investment. The chart shows the overall debt burden in the sector, which helps assess how the company finances its numerous and risky clinical programs.
Debt to book value of all companies in the market
Moleculin Biotech is a biopharmaceutical company with a broad portfolio of oncology drug candidates. Developing numerous projects requires significant capital. This chart shows that to finance such a vast and risky R&D pipeline, the company can rely solely on equity rather than debt.
P/E of the company, segment and market as a whole
P/E - MBRX
For Moleculin Biotech, a clinical-stage oncology company, P/E is not a useful metric. The company has no profit, and its valuation on this chart is arbitrary. The real value is a speculative bet on the success of its unique molecules in treating difficult-to-treat cancers.
P/E of the market segment - Oncology platforms
Moleculin Biotech is a clinical-stage biopharmaceutical company specializing in developing drugs to treat difficult-to-treat cancers. This chart shows the average valuation for the sector, providing investors with context for evaluating Moleculin's scientific pipeline and innovative approaches.
P/E of the market as a whole
Moleculin Biotech is a biopharmaceutical company developing drugs to treat difficult-to-treat cancers. Its valuation is a pure bet on the success of its research and development. It has no connection to the general economic cycles depicted by this chart. Moleculin's value is determined solely by the success or failure of its research.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company MBRX
Moleculin Biotech is a clinical-stage biopharmaceutical company developing a pipeline of drugs to treat difficult-to-treat cancers. This chart reflects investor expectations for its unique molecules targeting complex targets. The valuation is based on the potential of its drugs to treat brain, pancreatic, and other cancers.
%20P%2FE%20MBRX&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-MBRX&v=1772562665248 "Chart of the company's future (projected) P/E MBRX")
Future (projected) P/E of the market segment - Oncology platforms
Moleculin Biotech is an oncology company developing drugs to treat difficult-to-treat cancers. Its valuation relative to other biotechs reflects investor sentiment on its diversified pipeline of candidates. This reflects how the market views its scientific approach and the chances of success of at least one of its drugs in clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-platforms&v=1772562665273 "Future (projected) P/E graph of the market segment - Oncology platforms")
Future (projected) P/E of the market as a whole
Moleculin Biotech is an oncology company with a broad pipeline of drug candidates targeting difficult-to-treat cancers. Diversifying its pipeline is part of its strategy. This chart shows investors' overall risk appetite. For biotechs with multiple shots at goal, a positive environment is essential to fund parallel clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772562665308 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit MBRX
Moleculin Biotech is a clinical-stage oncology company developing a pipeline of drugs for the treatment of difficult-to-treat cancers. The financial performance shown here reflects the costs of conducting multiple clinical trials. The success of even one candidate could dramatically change the company's future.
Profit of companies in the market segment - Oncology platforms
Moleculin Biotech is an oncology company with a diversified pipeline of drug candidates. This chart reflects the financial health of the oncology sector as a whole. It helps assess the success of a multi-drug development strategy in one of the most complex and capital-intensive areas of medicine.
Overall market profit
Moleculin Biotech is an oncology company with a diversified pipeline of drug candidates. Its strategy is to attack cancer from multiple angles. For a clinical-stage company like MBRX, trial results are the key drivers. The overall economic situation, reflected in this chart, is a secondary factor.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company MBRX
Moleculin Biotech is a biotech company with a broad pipeline of oncology developments. Its future profit forecast is a composite estimate of the prospects of several of its drug candidates. This chart shows whether analysts believe at least one of its cancer treatment approaches will be successful.
%20profit%20of%20the%20company%20MBRX&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-MBRX&v=1772562665579 "Graph of future (projected) profit of the company MBRX")
Future (predicted) profit of companies in the market segment - Oncology platforms
Moleculin Biotech is a biopharmaceutical company developing a portfolio of drugs to treat difficult-to-treat cancers. Their developments target unique metabolic pathways in tumor cells. This chart shows the outlook for these oncology platforms, illustrating how a diversified approach to research can improve the chances of success in this risky field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-platforms&v=1772562665599 "Graph of future (predicted) profits of companies in a market segment - Oncology platforms")
Future (predicted) profit of the market as a whole
For Moleculin Biotech, an oncology company with a broad development pipeline, this chart is an indicator of investment activity. A favorable economic environment and investor appetite for risk allow them to raise funds for a wide range of clinical programs. During downturns, the focus may narrow to the most promising ones.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772562665616 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - MBRX
Moleculin Biotech is an oncology company with several drugs in development. This chart reflects investors' aggregate assessment of the potential revenue from its entire portfolio, discounted for clinical trial risks.
P/S market segment - Oncology platforms
Moleculin Biotech is a biopharmaceutical company developing a portfolio of drugs to treat difficult-to-treat cancers. This chart shows the average valuation in the oncology platform sector. It helps understand how investors view Moleculin's scientific approach and the potential of its drugs, which target unique metabolic pathways in cancer cells.
P/S of the market as a whole
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing drugs for the treatment of difficult-to-treat cancers. Its pipeline includes several candidates at various stages of development. The company's valuation is the combined potential of these developments. This graph helps assess the risks and potential rewards in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company MBRX
Moleculin Biotech is an oncology company with several drug candidates at various stages of development. Its valuation represents the combined success of its portfolio. The chart shows how investors assess the likelihood of at least one of its drugs reaching market and generating significant revenue.
%20P%2FS%20MBRX&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-MBRX&v=1772562665670 "The graph of the company's future (projected) P/S MBRX")
Future (projected) P/S of the market segment - Oncology platforms
Moleculin Biotech is an oncology company developing drugs targeting difficult-to-treat cancers. Its portfolio includes drugs that attack cancer cells through unique metabolic pathways. This chart shows how investors view its scientific platforms and potential for developing new treatments.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-platforms&v=1772562665679 "Future (projected) P/S market segment graph - Oncology platforms")
Future (projected) P/S of the market as a whole
This indicator summarizes expectations for the oncology market. For Moleculin Biotech, a company with a pipeline of developments against difficult-to-treat cancers, it reflects investors' risk appetite. Market optimism is essential for funding research into unique molecules aimed at bypassing tumor resistance mechanisms.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772562665694 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales MBRX
Moleculin Biotech is a clinical-stage oncology company developing a pipeline of drug candidates for the treatment of difficult-to-treat cancers. This chart reflects revenue from grants and partnerships. Future revenue is dependent on the success of clinical trials of its drugs, which target unique metabolic pathways in cancer cells.
Sales of companies in the market segment - Oncology platforms
Moleculin Biotech is an oncology company developing a portfolio of drugs to treat difficult-to-treat cancers. This chart shows the growth of the oncology platform market. Moleculin is focused on developing drugs that can overcome tumor resistance, one of the main challenges in modern chemotherapy.
Overall market sales
Moleculin Biotech, Inc. is a clinical-stage oncology company developing drugs for the treatment of difficult-to-treat cancers. Its market capitalization depends on research progress. The overall economic environment, shown in this chart, influences investor willingness to finance risky but socially significant biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company MBRX
Moleculin Biotech is an oncology company developing a portfolio of drugs to treat difficult-to-treat cancers. Its developments target unique metabolic processes in cancer cells. This chart reflects analysts' assessments of the scientific potential and commercial prospects of several of the company's clinical programs.
%20sales%20of%20the%20company%20MBRX&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-MBRX&v=1772562665980 "Schedule of future (projected) sales of the company MBRX")
Future (projected) sales of companies in the market segment - Oncology platforms
Moleculin Biotech is a biopharmaceutical company developing drugs to treat difficult-to-treat cancers. This chart shows expectations for the entire oncology platform sector. It reflects the overall need for new therapeutic approaches, which is the driving force behind companies like Moleculin.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-platforms&v=1772562666129 "Schedule of future (projected) sales of companies in the market segment - Oncology platforms")
Future (projected) sales of the market as a whole
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing drugs for the treatment of difficult-to-treat cancers. Its future depends on the results of clinical trials. This schedule, reflecting the state of the economy, affects the availability of capital to fund Moleculin's expensive oncology research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772562666150 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality MBRX
Moleculin Biotech is an oncology company with a pipeline of drugs in various stages of clinical trials. This chart shows the company is in the investment phase. Negative values reflect the costs of conducting multiple studies. The success of even one candidate could dramatically change the financial picture.
Market segment marginality - Oncology platforms
Moleculin Biotech is an oncology company developing a platform of drugs for the treatment of difficult-to-treat cancers. For a company in clinical trials, this chart serves as a benchmark. It shows the average profitability in the sector that Moleculin aims to achieve if its developments are successful and brought to market for patients.
Market marginality as a whole
Moleculin Biotech is a clinical-stage pharmaceutical company developing drugs for the treatment of difficult-to-treat cancers. This overall market profitability chart is irrelevant to the company. Its potential lies in its unique molecules and platforms. Success will be determined solely by the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company MBRX
Moleculin Biotech is a pharmaceutical company developing drugs to treat difficult-to-treat cancers. This chart shows a small but dedicated team managing a portfolio of clinical programs. Their size reflects their focus on research and development.
Share of the company's employees MBRX within the market segment - Oncology platforms
Moleculin Biotech is developing a platform of unique oncology drugs capable of overcoming drug resistance in tumors. This chart shows the percentage of leading chemists and oncologists working on this complex problem that the company attracts. It reflects its concentration of unique scientific expertise in the fight against the most resistant forms of cancer.
Number of employees in the market segment - Oncology platforms
Moleculin Biotech is a biopharmaceutical company developing drugs to treat difficult-to-treat cancers. Its focus on unique molecules and mechanisms of action offers hope to patients. This graph illustrates the constant search for new approaches in oncology, which requires scientists to think outside the box and possess a deep understanding of molecular biology.
Number of employees in the market as a whole
Moleculin Biotech is an oncology company developing a platform approach to treatment. This means that a single successful drug can become the basis for an entire pipeline of drugs. Such companies have enormous growth potential, and their success can create a significant number of high-quality jobs, making a significant contribution to the overall picture in this graph.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company MBRX (MBRX)
Moleculin Biotech is a biotech company focused on oncology. This chart represents a pure intellectual capital valuation. The company's value is based on market expectations for its pipeline of drug candidates (e.g., Annamycin). The chart demonstrates the high future value the market is pricing into these diverse oncology pipelines.
%20of%20the%20company%20MBRX%20(MBRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-MBRX-MBRX&v=1772562666445 "Chart of market capitalization per employee (in thousands of dollars) of the company MBRX (MBRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology platforms
Moleculin Biotech is developing a platform for developing oncology drugs. The company's value lies in its scientific approach. The chart shows how much investors are placing on their research team. A high value relative to the sector may indicate confidence in the uniqueness and broad potential of their technological platform.
%20by%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-platforms&v=1772562666480 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology platforms")
Market capitalization per employee (in thousands of dollars) for the overall market
Moleculin Biotech, Inc. is a biopharmaceutical company developing drugs to treat difficult-to-treat cancers. This chart shows the overall market performance, illustrating the market's hopes for a breakthrough in oncology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772562666489 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company MBRX (MBRX)
Moleculin Biotech is a clinical-stage biotech company focused on oncology. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company burns per scientist to conduct R&D and clinical trials.
%20Chart%20MBRX%20(MBRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-MBRX-MBRX&v=1772562666516 "Company Profit Per Employee (in thousands of dollars) Chart MBRX (MBRX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology platforms
Moleculin Biotech is an oncology company developing a portfolio of drugs to treat difficult-to-treat cancers. Its business is entirely focused on research and clinical trials. The negative profit per employee, likely shown in this chart, is typical for biotech companies at this stage and reflects the investment in its scientific team.
%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-platforms&v=1772562666563 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology platforms")
Profit per employee (in thousands of dollars) for the market as a whole
Moleculin Biotech (MBRX) is a clinical-stage biotech company developing a portfolio of drugs to treat difficult-to-treat cancers (including glioblastoma) and viruses. This is an R&D business. This chart shows the market average dollar return per employee. For MBRX (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772562666615 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee MBRX (MBRX)
Moleculin Biotech is a clinical-stage biopharmaceutical company working on treatments for complex cancers. This chart reflects the hopes and risks of biotech. The current low numbers are typical of the company's R&D, but they could change dramatically if its drugs are successful in the clinic.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-MBRX-MBRX&v=1772562666636 "Sales chart per company employee MBRX (MBRX)")
Sales per employee in the market segment - Oncology platforms
Moleculin Biotech is a clinical-stage biotech company developing drugs to treat difficult-to-treat cancers. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Moleculin's staff.
Sales per employee for the market as a whole
Moleculin Biotech is a clinical-stage biotechnology company developing drugs for the treatment of difficult-to-treat cancers. The company has no commercial products and, therefore, no revenue. This metric is currently irrelevant. The company's entire value lies in its R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company MBRX (MBRX)
Moleculin Biotech is an oncology company whose strategy is based on "reviving" old drugs that have previously failed. It's a risky approach. This chart shows the odds that their drugs will fail again. The bears believe these "old" molecules have no chance of proving their effectiveness in modern clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-MBRX-MBRX&v=1772562666756 "Short Shares Chart for the Company MBRX (MBRX)")
Shares shorted by market segment - Oncology platforms
Moleculin Biotech, Inc. is an oncology company developing drugs to treat difficult-to-treat cancers, including brain cancer and acute myeloid leukemia. This chart reflects the total short position in the biotech sector. High values indicate general investor skepticism about the success of risky clinical trials in oncology.
Shares shorted by the overall market
Moleculin Biotech is attacking cancer with a portfolio of early-stage drugs. Like any biotech, their survival depends on capital inflows for R&D. This chart measures the overall fear. When investors are pessimistic, they are unwilling to fund "research projects" for years to come. MBRX shares are selling off, fearing the company will run out of money before FDA approval.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator MBRX (MBRX)
Moleculin Biotech is an oncology company targeting difficult-to-treat tumors (including brain cancer). It's a clinical-stage biotech. This oscillator measures investor sentiment: it shows when positive trial data leads to "overbought" (above 70) or when delays lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-MBRX-MBRX&v=1772562666861 "RSI 14 indicator chart for the company's stock MBRX (MBRX)")
RSI 14 Market Segment - Oncology platforms
Moleculin Biotech is an oncology company developing drugs to treat difficult-to-treat cancers (including brain cancer). Their portfolio targets unique tumor metabolic pathways. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire speculative segment is overheated.
RSI 14 for the overall market
For Moleculin Biotech, a biotech company in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MBRX (MBRX)
Moleculin Biotech is an oncology company with a broad R&D portfolio targeting difficult-to-treat cancers (e.g., brain cancer, leukemia). This chart shows the analysts' average 12-month forecast. It represents their collective speculative bet that one of their candidates will succeed in the clinic.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MBRX-MBRX&v=1772562666911 "A chart showing analyst consensus forecasts for the expected stock price. MBRX (MBRX)")
The difference between the consensus estimate and the actual stock price MBRX (MBRX)
Moleculin is an oncology company developing a pipeline of drug candidates for the treatment of difficult-to-treat tumors (including brain cancer). This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in this diversified, yet risky, R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MBRX-MBRX&v=1772562666930 "A chart showing the difference between the consensus forecast and the actual stock price. MBRX (MBRX)")
Analyst consensus forecast for stock prices by market segment - Oncology platforms
Moleculin is an R&D biotech company developing drugs to treat the most stubborn cancers (brain and pancreatic tumors). This is a high-risk bet. This chart reflects the overall expectations of analysts across the oncology sector. It shows whether experts believe a breakthrough in the treatment of these complex tumors is possible.
Analysts' consensus forecast for the overall market share price
Moleculin Biotech is a biotech company specializing in developing drugs to treat difficult-to-treat, drug-resistant cancers (including brain tumors). This chart reflects the overall market "risk appetite." For MBRX, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index MBRX
Moleculin is a biotech R&D company focused on complex cancers. Their signature product is a platform (Annamycin, WP1066) that targets highly resistant tumors (including brain metastases) that are untreatable. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative valuation of their (very risky) pipeline.
AKIMA Market Segment Index - Oncology platforms
Moleculin Biotech (MBRX) is an oncology company focused on intractable targets. They are developing drugs (WP1066, Annamycin) for the treatment of difficult-to-treat cancers, including brain cancer and leukemia. The chart shows the segment average, helping investors assess how this high-risk strategy compares to the oncology industry average.
The AKIM Index for the overall market
Moleculin Biotech is a pharmaceutical company developing drugs to treat difficult-to-treat tumors and viruses. This chart, which reflects the market average, provides a macro backdrop. It helps assess how MBRX, a speculative scientific story, compares to overall economic trends and clinical trial data.
